Pacific Biosciences Of California, Inc. · NASDAQ:PACB
Pacific Biosciences Of California — Shareholder Meeting (May 2022)
14 slides from Pacific Biosciences Of California's shareholder meeting presentation, May 9, 2022
Slide 1: PacBio Management Stockholder Engagement
1 May 9, 2022 | PacBio Management Stockholder Engagement
Slide 2: Safe Harbor Statement
2 Safe Harbor Statement Forward Looking Statements All statements in this presentation that are not historical are forward - looking statements within the meaning of the Private Sec urities Litigation Reform Act of 1995, and include statements relating to the intent, belief or current expectations,
Slide 3: We create some of the world's most advanced sequencing technologies
3 We create some of the world’s most advanced sequencing technologies ENABLING THE PROMISE OF GENOMICS TO BETTER HUMAN HEALTH
Slide 4: PacBio is a leader in highly accurate sequencing technologies
4 PacBio is a leader in highly accurate sequencing technologies Sequel IIe: Our current long read sequencer SBB by PacBio – Mid throughout short read sequencer expected 1H 2023 Dedicated consumables Sample prep and extraction kits Software, informatics and support San Diego Menlo Park Baltimore Lond
Slide 5: Decade of innovation driving toward large scale, long read whole genome sequencing
5 Decade of innovation driving toward large scale, long read whole genome sequencing Feb 2010 RS System Oct 2015 Sequel System Oct 2019 HiFi Chemistry Oct 2020 Sequel IIe System April 2019 Sequel II System Large scale HiFi adoption Increased Throughput >10,000 - fold Increased Read Length >100 - fol
Slide 6: Transforming PacBio 2021 to present
6 Transforming PacBio 2021 to present Nanobind technology extends our capabilities in extraction + sample prep Sequencing by binding adds differentiated short read technology ~25% more HiFi data 3 × lower DNA input PacBio HUMAN GENOMICS Launched HiFiViral as PacBio’s first kitted solution PacBio MIC
Slide 7: Revenue and Sequel II/IIe installed base growth
7 79 93 79 91 79 131 2016 2017 2018 2019 2020 2021 2022E 2021 was inflection point in revenue and installed base growth $160 (+23%) $170 (+30%) Guidance range 1 1 Based on 2022 full year guidance provided on May 4, 2022. Outlook represents management’s guidance only as of such date. 114 203 374 424
Slide 8: 2022 Annual Meeting of Stockholders
8 2022 Annual Meeting of Stockholders Proposal Recommendation Elect each of the three Class III directors to serve for a three - year term FOR Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the FY ending December 31, 2022 FOR Approve 18
Slide 9: Director nominees include breadth of experience in genomics, commercialization, and business development
9 David Botstein, PhD Chief Scientific Officer of Calico Life Sciences, LLC • Former Professor of Genomics, Emeritus at Princeton University and Director of the Lewis - Sigler Institute for Integrative Genomics . • 1990 - 2003 : Chairman of Dept of Genetics at Stanford . • 1987 - 1990 : VP for Scien
Slide 10: Board members not up for reelection
10 Board members not up for reelection – reflects decades of experience in finance, genomics, medicine, and operational excellence John Milligan, PhD, Chairman of the Board Former President and CEO of Gilead. Held several other leadership roles at Gilead over a 29 - year career . Christian Henry Pre
Slide 11: Current board makeup
11 Current board makeup 67% 33% Male Female 11% 89% African American or Black White Demographic Background Gender Identity
Slide 12: Equity awards are critical to attracting, retaining and incentivizing top talent
12 Equity awards are critical to attracting, retaining and incentivizing the top talent required to execute on our transformation Seeking approval for 18 million additional shares under our 2020 Equity Incentive Plan; currently have ~1 million shares available If approved, we anticipate that we like
Slide 13: 2020 Equity Incentive Plan – Historical burn rate and overhang
13 2020 Equity Incentive Plan – Historical burn rate 1 average below peer median and below ISS; overhang including 18 million shares is <20% 1 1 Burn rate based on ISS - Adjusted Burn Rate which places a multiple on grants based on 3 - year stock price volatility 2 ISS 3 - Year benchmark cap for Pha
Slide 14: 2022 Annual Meeting of Stockholders
14 2022 Annual Meeting of Stockholders Proposal Recommendation Elect each of the three Class III directors to serve for a three - year term FOR Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the FY ending December 31, 2022 FOR Approve 18
Pacific Biosciences of California — Shareholder Meeting (May 2022) on 6ix